scholarly journals Association between the type of allergen and T-helper 2 mediated inflammation in allergic reactions: a systematic review and a meta-analysis

2022 ◽  
Vol 50 (1) ◽  
pp. 37-50
Author(s):  
Elina Nepolo ◽  
Bongani B Nkambule ◽  
Phiwayinkosi V Dludla ◽  
Fransina Ndevahoma ◽  
Tawanda M Nyambuya

Objectives: To determine whether the levels of T-helper (TH) 2 cytokines (interleukin (IL)-4 and IL-5) in allergic reactions are allergen dependent and evaluate the impact of various treatment strategies on the levels of these cytokines.Methods: The PubMed search engine was used from inception until January 2021. The random-effects residual maximum likelihood model was performed, and effect sizes were estimated using the Hedge’s g statistic. All data analysis was performed using STATA 16.0 (StataCorp LP, TX, USA). Results: Fourteen studies reporting on 794 participants were included in this study. House dust mite was associated with eliciting a stronger immune response mediated by both IL-4 and IL-5 when compared to pollen. Whereas a mixture of house dust mite and pollen was associated with IL-4-weighted inflammation. Comparisons of IL-4 and IL-5 levels amongst the allergens showed significant differences. The treatment with anti-corticosteroids or allergen-specific immunotherapy was effective in normalising the TH2 responses and alleviating allergy symptoms.Conclusion: TH2-mediated inflammation in allergic reactions is allergen-dependent. Therefore, the type of allergen should be considered when using cytokine-targeting biologics in allergic reactions.

2010 ◽  
Vol 75 (1) ◽  
pp. 19-26
Author(s):  
Lidija Burazer ◽  
Katarina Milovanovic ◽  
Tanja Cirkovic-Velickovic ◽  
Marija Gavrovic-Jankulovic

Allergen-specific immunotherapy with house dust mite (HDM) allergen extracts can effectively alleviate the symptoms of allergic rhinitis and asthma. The efficacy of the immunotherapeutic treatment is highly dependent on the quality of house dust mite vaccines. This study was performed to assess the stability of house dust mite allergen vaccines prepared for sublingual immunotherapy. Lyophilized Dermatophagoides pteronyssinus (Dpt) mite bodies were the starting material for the production of sublingual vaccines in four therapeutic concentrations. The stability of the extract for vaccine production, which was stored below 4 ?C for one month, showed consistence in the protein profile in SDS PAGE. ELISA-inhibition showed that the potencies of Dpt vaccines during a 12 month period were to 65-80 % preserved at all analyzed therapeutic concentrations. This study showed that glycerinated Dpt vaccines stored at 4?C preserved their IgE-binding potential during a 12 month period, implying their suitability for sublingual immunotherapeutic treatment of HDM allergy.


Allergy ◽  
2020 ◽  
Vol 75 (6) ◽  
pp. 1457-1460 ◽  
Author(s):  
Tadech Boonpiyathad ◽  
Panitan Pradubpongsa ◽  
Wat Mitthamsiri ◽  
Pattraporn Satitsuksanoa ◽  
Alain Jacquet ◽  
...  

Immunity ◽  
2016 ◽  
Vol 44 (2) ◽  
pp. 259-273 ◽  
Author(s):  
André Ballesteros-Tato ◽  
Troy D. Randall ◽  
Frances E. Lund ◽  
Rosanne Spolski ◽  
Warren J. Leonard ◽  
...  

2017 ◽  
Vol 131 (11) ◽  
pp. 997-1001 ◽  
Author(s):  
E Sahin ◽  
D Dizdar ◽  
M E Dinc ◽  
A A Cirik

AbstractBackground:Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis.Methods:The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients).Results:The symptom scores before allergen-specific immunotherapy were significantly higher than those obtained after 3 years of allergen-specific immunotherapy and 10 years after allergen-specific immunotherapy (p < 0.0175). There were no significant differences between the scores obtained at 3 years and 10 years after allergen-specific immunotherapy (p > 0.0175).Conclusion:Subcutaneous immunotherapy is an effective treatment for house dust mite induced allergic rhinitis.


2009 ◽  
Vol 39 (10) ◽  
pp. 1597-1610 ◽  
Author(s):  
L. G. Gregory ◽  
B. Causton ◽  
J. R. Murdoch ◽  
S. A. Mathie ◽  
V. O'Donnell ◽  
...  

2017 ◽  
Vol 31 (3) ◽  
pp. 156-160 ◽  
Author(s):  
Jianjun Chen ◽  
Yue Zhou ◽  
Yanjun Wang ◽  
Yiwu Zheng ◽  
Xuxin Lai ◽  
...  

Background Specific immunoglobulin E (sIgE) and sIgG4 to house-dust mite (HDM) major allergens during allergen immunotherapy (AIT) and their clinical relevance remain unclear. Objective To investigate the variation of sIgE and sIgG4 to HDM major allergens and the correlation with clinical responses during AIT in patients with allergic rhinitis. Methods Thirty-nine patients with HDM allergy were divided into the AIT group (taking immunotherapy) and the control group (medication only use). The AIT group was subdivided into negative clinical responses to AIT (nAIT) group and positive clinical responses to AIT (pAIT) group according to symptom relief and subjective evaluation. sIgE and sIgG4 to Dermatophagoides pteronyssinus (Dp) and Dermatophagoides farinae (Df), and their group 1 and group 2 major allergens (Dp1, Df1, Dp2, and Df2) were measured before AIT, at 6 months, and at 1 year after starting AIT. Results Dp2, Df, and Df2 sIgE values decreased significantly in the pAIT group versus the nAIT group after 1 year of AIT (median values of delta change were Dp2, -10.09 versus 5.89 kU/L, p = 0.001; median values of Df were —9.69 versus 17.54 kU/L, p = 0.004; median values of Df2 were -11.06 versus 20.08 kU/L, p = 0.013). There was a robust increase in the sIgG4 values to Dp, Df, and their major allergens in both the pAIT and the nAIT groups overall after 1 year of treatment. Conclusion Patients with a positive response to AIT showed a significant reduction of HDM group 2 sIgEs compared with those with a negative response to AIT, which indicated that a decrease in group 2 sIgEs could be a marker that reflected AIT clinical efficacy.


Immunity ◽  
2013 ◽  
Vol 38 (2) ◽  
pp. 322-335 ◽  
Author(s):  
Maud Plantinga ◽  
Martin Guilliams ◽  
Manon Vanheerswynghels ◽  
Kim Deswarte ◽  
Filipe Branco-Madeira ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document